Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect
1999
Medroxyprogesterone Acetate and Its Effects on Breast Cancer Cells
Sample size: 2
publication
Evidence: moderate
Author Information
Author(s): Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H
Primary Institution: Kawasaki Medical School
Hypothesis
Does medroxyprogesterone acetate inhibit interleukin 6 secretion from breast cancer cells?
Conclusion
Medroxyprogesterone acetate reduces interleukin 6 secretion from breast cancer cells, which may help prevent cachexia in patients.
Supporting Evidence
- Medroxyprogesterone acetate decreased IL-6 secretion in a dose-dependent manner.
- The treatment did not affect tumor growth in the mice.
- Serum IL-6 levels were significantly decreased in treated mice.
Takeaway
A medicine called medroxyprogesterone acetate can help stop a substance that makes people with cancer lose weight.
Methodology
The study examined the effects of medroxyprogesterone acetate on interleukin 6 secretion in a human breast cancer cell line and in nude mice.
Participant Demographics
Female nude mice bearing KPL-4 transplanted tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website